SLP is no longer listed. Its last trade on record was Oct 7, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
SLP trades 0.0% below Wall Street's consensus target of $18.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SLP achieves its forward estimates and maintains a stable P/E multiple of 21.3x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Simulations Plus, Inc. (SLP) has a Wall Street consensus price target of $18.50, based on estimates from 9 covering analysts.
Analyst price targets range from a low of $18.50 to a high of $18.50, representing a 0% spread in expectations. The median target of $18.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SLP trades at a forward P/E of 21.3x. Analysts expect EPS to grow +117.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $12.94, with bear and bull scenarios of $8.16 and $17.05 respectively. Model confidence stands at 39/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 VEEVVeeva Systems Inc. | $49.3B | $303.73 | $300.50 | -1.1% | Buy | 32.9x | 43 |
 CERTCertara, Inc. | $1.9B | $12.05 | $10.13 | -15.9% | Hold | 35.4x | 17 |
 SCYXSCYNEXIS, Inc. | $22M | $3.50 | — | — | — | — | — |
 DSGNDesign Therapeutics, Inc. | $638M | $10.21 | $26.00 | +154.7% | Buy | — | 7 |
 SDGRSchrödinger, Inc. | $2.2B | $29.82 | $19.00 | -36.3% | Buy | — | 12 |
 RXRXRecursion Pharmaceuticals, Inc. | $1.8B | $3.52 | $5.90 | +67.6% | Hold | — | 10 |
 ABSIAbsci Corporation | $1.7B | $10.17 | $13.67 | +34.4% | Buy | — | 13 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 AAgilent Technologies, Inc. | $49.4B | $174.76 | $174.29 | -0.3% | Buy | 28.2x | 41 |
 CRLCharles River Laboratories International, Inc. | $16.3B | $337.52 | $308.36 | -8.6% | Buy | 29.7x | 37 |
Quick answers to the most common questions about buying SLP stock.
The consensus price target for SLP is $18.5, close to the current price of $N/A (0.0% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
SLP has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $18.5 implies 0.0% upside from current levels.
SLP trades at a forward P/E of 21.2644x, representing a moderate valuation. With analysts targeting $18.5 (0.0% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $18.5 for SLP, while the most conservative target is $18.5. The consensus of $18.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $17 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
SLP is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SLP stock forecast based on 9 Wall Street analysts shows a consensus price target of $18.5, with estimates ranging from $18.5 (bear case) to $18.5 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $13, with bear/bull scenarios of $8/$17.
Our quantitative valuation model calculates SLP's fair value at $13 (base case), with a bear case of $8 and bull case of $17. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 39/100.
SLP trades at a forward P/E ratio of 21.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SLP appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $18.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SLP analyst price targets range from $18.5 to $18.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $18.5 consensus represents the middle ground. Our model's $8-$17 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.